National and Kapodistrian University of Athens
Η θεραπευτική αξία της ανθρώπινης ανασυνδιασμένης ερυθροποιητίνης σε έγκυους φορείς της β-μεσογειακής αναιμίας με σοβαρή αναιμία στο τρίτο τρίμηνο της κύησης
Abstract
dc:descriptionThe aim of this study was to investigate the benefits from the use of human recombinant erythropoietin (rhHEPO) in the third trimester of pregnancy in women with severe anemia due to β-thallasemia – trait . We recruited 2 groups of women. The group A consisted of 20 pregnant women, with severe anemia who received human recombinant erythropoietin, 10000 IU subcutaneously, thrice per week. Additionally the patients of group A received daily 300mg of iron supplements orally.The group B consisted of 20 pregnant women, with severe anemia as well, who received 1 to 3 units of packed red cells. Three blood parameters were checked, the value of haematocrit, hemoglobin concentration and the reticulocyte levels, every 2 weeks. Our study showed a significant improvement of all hematological parameters in the rhHEPO group, compared with the control group. CONCLUSION: The use of human recombinant erythropoietin seems to be a reliable therapy for pregnant women with severe anemia due to β-thallasemia trait. Furthermore this treatment is also safe for the mother because minimizes the risk of vertical viral infections caused by blood transfusion.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karantzis, Panagiotis
- Καραντζής, Παναγιώτης
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29725